Molecular aspects of the antiviral response against hepatitis C virus implicated in vaccines development

被引:1
作者
Soledad Llanes, Maria [1 ]
Soledad Palacios, Natalia [1 ]
Piccione, Magali [1 ]
Guillermina Ruiz, Maria [1 ]
Layana, Carla [1 ,2 ]
机构
[1] Univ Nacl Noroeste Buenos Aires, Dept Ciencias Basicas & Expt, Buenos Aires, DF, Argentina
[2] Univ Nacl La Plata, Fac Ciencias Exactas, Ctr Reg Estudios Genom, Buenos Aires, DF, Argentina
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2015年 / 33卷 / 04期
关键词
Hepatitis C; Vaccines; Treatment; I CLINICAL-TRIAL; CANDIDATE VACCINE; PLUS RIBAVIRIN; NEUTRALIZING ANTIBODIES; THERAPEUTIC VACCINATION; IMMUNE-RESPONSES; PROTEIN; PHASE; INFECTION; PARTICLES;
D O I
10.1016/j.eimc.2013.12.012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Hepatitis C is a contagious liver disease caused by hepacivirus of the Flaviviridae family. It has a RNA genome, a unique highly variable molecule. It encodes ten proteins which are necessary to infect cells and multiply. Replication occurs only in hepatocytes. Because of its wide genomic variability and the absence of symptoms, it is difficult to make an early diagnosis and successful treatment. In this review we analyze the molecular mechanism by which the virus infects the hepatocytes and causes the disease. We focused the analysis on different therapies, with the possibility of improving treatment with the use of new specific vaccines. We highlight the use of new therapies based on nucleic acids, mainly DNA vectors. In the near future, once this treatment is adequately evaluated in clinical trials, and the costs are calculated, it could be a very beneficial alternative to conventional methods. (C) 2013 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. All rights reserved.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 66 条
[21]   Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasome [J].
Franck, N ;
Le Seyec, J ;
Guguen-Guillouzo, C ;
Erdtmann, L .
JOURNAL OF VIROLOGY, 2005, 79 (05) :2700-2708
[22]   Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults [J].
Frey, Sharon E. ;
Houghton, Michael ;
Coates, Stephen ;
Abrignani, Sergio ;
Chien, David ;
Rosa, Domenico ;
Pileri, Piero ;
Ray, Ranjit ;
Di Bisceglie, Adrian M. ;
Rinella, Paola ;
Hill, Heather ;
Wolff, Mark C. ;
Schultze, Viola ;
Han, Jang H. ;
Scharschmidt, Bruce ;
Belshe, Robert B. .
VACCINE, 2010, 28 (38) :6367-6373
[23]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[24]   Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance [J].
Ge, Dongliang ;
Fellay, Jacques ;
Thompson, Alexander J. ;
Simon, Jason S. ;
Shianna, Kevin V. ;
Urban, Thomas J. ;
Heinzen, Erin L. ;
Qiu, Ping ;
Bertelsen, Arthur H. ;
Muir, Andrew J. ;
Sulkowski, Mark ;
McHutchison, John G. ;
Goldstein, David B. .
NATURE, 2009, 461 (7262) :399-401
[25]   Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only [J].
Giannini, Sandra L. ;
Hanon, Emmanuel ;
Moris, Philippe ;
Van Mechelen, Marcelle ;
Morel, Sandra ;
Dessy, Francis ;
Fourneau, Marc A. ;
Colau, Brigitte ;
Suzich, Joann ;
Losonksy, Genevieve ;
Martin, Marie-Therese ;
Dubin, Gary ;
Wettendorff, Martine A. .
VACCINE, 2006, 24 (33-34) :5937-5949
[26]   A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals [J].
Gowans, Eric J. ;
Roberts, Stuart ;
Jones, Kathryn ;
Dinatale, Irene ;
Latour, Philippe A. ;
Chua, Brendan ;
Eriksson, Emily M. Y. ;
Chin, Ruth ;
Li, Shuo ;
Wall, Dominic M. ;
Sparrow, Rosemary L. ;
Moloney, Jude ;
Loudovaris, Maureen ;
Ffrench, Rosemary ;
Prince, H. Miles ;
Hart, Derek ;
Zeng, Weng ;
Torresi, Joseph ;
Brown, Lorena E. ;
Jackson, David C. .
JOURNAL OF HEPATOLOGY, 2010, 53 (04) :599-607
[27]  
Habersetzer F, 2009, CURR OPIN MOL THER, V11, P456
[28]  
Halliday J, 2011, EXPERT REV VACCINES, V10, P659, DOI [10.1586/erv.11.55, 10.1586/ERV.11.55]
[29]   Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway [J].
Heim, MH ;
Moradpour, D ;
Blum, HE .
JOURNAL OF VIROLOGY, 1999, 73 (10) :8469-8475